StemCyte International (TPE:4178) EBIT: NT$-163.1 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:4178 StemCyte International Ltd TPE:4178
7 GF Score
Price NT$18.40
! 4 Warning Signs
View Full Analysis

What is StemCyte International EBIT?

StemCyte International TPE:4178 -2.39% 7 EBIT is NT$-163.1 Mil as of Mar. 2026. GuruFocus rates TPE:4178 with a GF Score™ of 7/100. The stock has 4 warning signs investors should review.

StemCyte International's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was NT$-32.9 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was NT$-163.1 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. StemCyte International's annualized ROC % for the quarter that ended in Mar. 2026 was -25.31%. StemCyte International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -21.53%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. StemCyte International's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -7.99%.

StemCyte International  (TPE:4178) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

StemCyte International's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-229.948 * ( 1 - 0% )/( (912.703 + 904.604)/ 2 )
=-229.948/908.6535
=-25.31 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3090.213 - 85.827 - ( 2091.683 - max(0, 250.426 - 2610.034+2091.683))
=912.703

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3103.113 - 73.571 - ( 2124.938 - max(0, 244.299 - 2637.624+2124.938))
=904.604

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

StemCyte International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-131.444/( ( (323.97 + max(290.034, 0)) + (316.356 + max(290.737, 0)) )/ 2 )
=-131.444/( ( 614.004 + 607.093 )/ 2 )
=-131.444/610.5485
=-21.53 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(90.307 + 406.846 + 15.276) - (85.827 + 0 + 136.568)
=290.034

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(91.595 + 402.178 + 12.978) - (73.571 + 0 + 142.443)
=290.737

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

StemCyte International's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-163.085/2041.387
=-7.99 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

StemCyte International EBIT Related Terms

StemCyte International EBIT Historical Data

* Premium members only.

The historical data trend for StemCyte International's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

StemCyte International EBIT Chart

StemCyte International Annual Data
Trend Dec22 Dec23 Dec24 Dec25
EBIT
-125.38 -329.22 -193.93 -159.83

StemCyte International Quarterly Data
Dec22 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only -29.60 -49.36 -38.92 -41.94 -32.86

TPE:4178 vs VRTX, REGN, RVMD: EBIT Comparison

For the Biotechnology subindustry, StemCyte International's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

StemCyte International EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, StemCyte International's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where StemCyte International's EV-to-EBIT falls into.


TPE:4178
7GF Score
StemCyte International Ltd TPE:4178
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

StemCyte International EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-163.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$-163.1 Mil mean?
StemCyte International (TPE:4178) has a EBIT of NT$-163.1 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on StemCyte International.
Is StemCyte International's EBIT too high?
StemCyte International's current EBIT is NT$-163.1 Mil. Overall, StemCyte International has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does StemCyte International's EBIT compare to VRTX and REGN?
StemCyte International's EBIT of NT$-163.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on StemCyte International. StemCyte International's current EBIT is NT$-163.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCyte International stock overvalued right now?
StemCyte International (TPE:4178) has a current EBIT of NT$-163.1 Mil. The current EBIT is NT$-163.1 Mil. StemCyte International's overall GF Score™ is 7/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For StemCyte International (TPE:4178), the current EBIT is NT$-163.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

StemCyte International Business Description

Address Zhongxiao East Raod, 9th Floor-2, No. 508, Section 7, Nangang District, Taipei, TWN
StemCyte International Ltd is engaged in developing new stem cell drugs and test, process, and store umbilical cord blood (UCB)-related cells. The company's main operating activities are providing umbilical cord blood collection, processing and storage services. Its reportable segments are the United States, Taiwan, and Others. The majority of revenue is derived from the United States.
7GF Score

Get the complete analysis for TPE:4178

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$18.40
Price